Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and ...
Sam Altman, CEO of OpenAI said the company is committed to spending $1.4 trillion to develop 30 gigawatts of computing resources.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback